Abstract
British Columbia, Quebec and Nova Scotia are poised to begin a clinical trial to study the safety and effectiveness of giving younger girls 2 doses of a new vaccine against human papillomavirus, instead of the current 3-dose regimen. “Our study will look to see if 2 doses of Gardasil [

This publication has 0 references indexed in Scilit: